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Fine-mapping of the cell-division cycle, notably the
identification of mitotic kinase signaling pathways,
provides novel opportunities for cancer-drug discov-
ery. As a key regulator of multiple steps during mitotic
progression across eukaryotic species, the serine/
threonine-specific Polo-like kinase 1 (Plk1) is highly
expressed in malignant cells and serves as a negative
prognostic marker in specific human cancer types
[1–4]. Here, we report the discovery of a potent
small-molecule inhibitor of mammalian Plk1, BI 2536,
which inhibits Plk1 enzyme activity at low nanomolar
concentrations. The compound potently causes a mi-
totic arrest and induces apoptosis in human cancer
cell lines of diverse tissue origin and oncogenome
signature. BI 2536 inhibits growth of human tumor xe-
nografts in nude mice and induces regression of large
tumors with well-tolerated intravenous dose regimens.
In treated tumors, cells arrest in prometaphase, accu-
mulate phosphohistone H3, and contain aberrant mi-
totic spindles. This mitotic arrest is followed by a surge
in apoptosis, detectable by immunohistochemistry
and noninvasive optical and magnetic resonance
imaging. For addressing the therapeutic potential of
Plk1 inhibition, BI 2536 has progressed into clinical
studies in patients with locally advanced or metastatic
cancers.
Results and Discussion
Based on the essential role of Plk1 during mitosis of all
proliferating cells, as well as its enriched expression in
human cancer tissues (Figure S1 in the Supplemental
Data available with this article online), we screened
*Correspondence: norbert.kraut@vie.boehringer-ingelheim.coma diverse library of organic compounds for their ability
to inhibit the catalytic activity of Plk1. We identified the
class of dihydropteridinones as Plk1 inhibitors that were
then further tailored for potency, selectivity, and ability to
modulate Plk1 in proliferating cells. The dihydropteridi-
none BI 2536 (Figure 1A) blocked human Plk1 with a
half-maximal inhibitory concentration (IC50) of 0.83 nM
(Figure S2) and equipotently blocked mouse and rat
Plk1. This compound showed a more than 1000-fold
selectivity relative to a panel of 63 other protein kinases
(Table S1), but it also affected the activities of Plk2 at
an IC50 of 3.5 nM and, to a slightly lesser extent, the ac-
tivity of Plk3 (IC50 9.0 nM). For technical reasons, we
have not been able to assess the effect of BI 2536 on
Plk4, a kinase showing only limited homology to Plk1 in
its kinase domain [5]. Taken together, these results show
that BI 2536 potently and selectively inhibits Plk1 in vitro.
The effect of BI 2536 on the cell-cycle profile of cancer
cells grown in vitro was assessed by immunofluores-
cence microscopy and flow cytometry. Exceeding
a 100-fold concentration range starting at 10 nM, BI
2536 caused HeLa cells to accumulate with a 4N DNA
content (Figure 1B), indicative of a cell-cycle block in ei-
ther G2 phase or mitosis. To assess specific cellular ef-
fects of BI 2536, we treated HeLa cells with increasing
doses for 2 hr and processed them for a-tubulin immu-
nofluorescence. Again, first cell-cycle effects were ob-
served at 10 nM, whereas at concentrations as low as
25 nM, anaphase and telophase figures were absent
and we observed accumulation of mitotic cells with ab-
errant spindles (Figure 1C). Remarkably, at 50 nM con-
centration, the appearance and distribution of pheno-
types was almost identical to those observed upon
treatment with Plk1 RNAi (Figures 1C and 1D) [6, 7].
The most prominent and severe phenotype in both
RNAi and inhibitor-treated samples were monopolar
spindles, which we refer to as ‘‘Polo’’ spindles, circled
by a ring of chromosomes (Figure 1D) [6–8]. A homoge-
nous population of monopolar ‘‘Polo’’ spindles was
observed at 100 nM and concentrations of up to 1 mM
(Figures 1C and 1D).
We examined the effects of BI 2536 on cell-cycle pro-
gression and apoptosis in synchronized HeLa cultures
by determining the DNA content and induction of
cleaved PARP p85 fragments, respectively (Figure 1E).
HeLa cells released into regular culture media pro-
gressed through S and G2/M and then reentered G1
phase with no evidence of apoptosis (Figure 1E, left
panels). In contrast, cells released into media with
60 nM BI 2536 progressed through S phase normally
and then arrested in G2/M. Between 24 and 48 hr after
release, these cells showed a sub-G1 DNA peak, indica-
tive of DNA breakdown and apoptosis, and they accu-
mulated cleaved PARP p85 fragments (Figure 1E, right
panels); this finding is consistent with the reported
effects of Plk1 RNAi in cancer cells [7, 9].
It was recently reported that Plk1 RNAi only results
in a strong mitotic arrest in cancer cells but not in
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317Figure 1. BI 2536 Induces Mitotic Arrest and Subsequent Apoptosis in Human Cells
(A) Chemical structure of the ATP-competitive kinase inhibitor, BI 2536, derived from a novel chemical series, the dihydro-pteridinones
(WO 03/020722).
(B) FACS profile of exponentially growing HeLa-S3 cells treated for 24 hr by BI 2536 with concentrations ranging 10 nM–1 mM. Cells accumulate
4N DNA content, indicative of G2/M arrest. The mitotic figures observed in BI 2536-treated cultures of HeLa cells displayed abnormal mitotic
figures at EC50 values closely matching the induction of a G2/M arrest (data not shown). Note that the 8N peak reflects cell aggregates rather
than induction of binucleated cells.
(C) HeLa cells treated with increasing concentrations of BI 2536 for 2 hr, fixed, and stained for a-tubulin and DNA for identification of mitotic
stages. Mitotic arrest is evident already at concentrations of 25 nM, and phenotype stabilizes at 100 nM with monopolar ‘‘Polo’’ spindles typical
for Plk1 inhibition. n = 100 for each.
(D) Phenotype of HeLa cells arrested by 100 nM BI 2536. a-tubulin is shown in red; DNA is shown in cyan. Mad2 labels kinetochores signifying
checkpoint-induced mitotic arrest. The scale bar represents 10 mm.
(E) HeLa S3 cells synchronized at the G1/S transition by thymidine treatment were incubated with 60 nM BI 2536. At the time points indicated,
cells were analyzed by FACS and by western blotting for cleaved PARP p85 fragments. Starting at 24 hr, a strong signal for fragmented DNA and
cleaved PARP is detected, indicative of apoptosis.
(F) Immunofluorescence analysis of hTERT-RPE1 cells reveals almost identical dose response to HeLa cells. Cells were analyzed as for (C),
n = 100 for each.
(G) Mitotic phenotypes of hTERT-RPE1 cells treated with 100 nM BI 2536. Labels are as shown in (D).noncancer cell lines [10]. To analyze the effects of BI
2536 in nontransformed cycling cells, we tested the
compound in hTERT-RPE1 cells, a noncancer human
retinal pigment epithelial cell line that has been immor-
talized by stable expression of human telomerase re-
verse transcriptase [11]. We observed a dose response
with a distribution of phenotypes that was very similar
to the one seen in HeLa cells (Figure 1F). At 100 nM,
approximately 70% of mitotic cells showed a typical
‘‘Polo’’ phenotype, whereas the remaining approxi-
mately 30% were arrested with aberrant spindles lack-
ing focused poles and containing unaligned chromo-
somes (Figure 1G).
In addition to HeLa cells, BI 2536 potently inhibited the
proliferation of a panel of 32 human cancer cell lines, rep-
resenting diverse organ derivations (including carcino-
mas of the breast, colon, lung, pancreas, and prostate,
melanomas, and hematopoietic cancers) and variedpatterns of tumor suppressor or oncogene mutations
(includingRB1,TP53,PTEN, andKRAS status) (Figure 2).
The half-maximal effective concentration (EC50) values
in this cell panel ranged 2–25 nM, whereas a concentra-
tion of 100 nM of BI 2536 was typically sufficient for
inducing a complete mitotic arrest, as described above
for HeLa cells. The proliferation of exponentially growing
hTERT-RPE1, human umbilical vein endothelial cells
(HUVECs), and normal rat kidney (NRK) cells was
blocked at EC50 values ranging 12–31 nM, indicating a
comparable sensitivity of cycling nontransformed cells
to BI 2536.
The multitargeted inhibitor ON01910 [12] was, at one
point, considered to affect not only Cdk1 and various ty-
rosine kinases but also Plk1 function [13]. We therefore
compared the effects of this compound to the effects
of BI 2536. However, in our Plk1 in vitro kinase assay,
ON01910 showed no inhibition up to a concentration
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318Figure 2. BI 2536 Blocks the Proliferation of
Multiple Human Cancer-Cell Types
Shown for the panel of cultured cancer cell
lines; changes in cell viability were quantified
by Alamar Blue assay, 72 hr after initiation of
BI 2536 treatment or the vehicle control. The
bar chart summarizes the mean values for
half-maximal growth inhibition for each cell
line (EC50 values; [nM]) on a logarithmic scale.
The mutational status of the respective can-
cers for RB1, TP53, PTEN, and KRAS are
given. Abbreviations are as follows: WT,
wild-type; mt, mutated; -, not determined;
WT*, wild-type genes but respective proteins
inactivated by human papilloma virus early
gene products; SQCC-HN, squamous-cell
carcinoma of the head and neck.of 30 mM. Although the compound effectively blocked
cell proliferation of Hela S3 cells at an EC50 of 45 nM,
we were unable to find a concentration range in these
cells where phenotypes were observed that were remi-
niscent of Plk1 RNAi: Multipolar spindles but no mono-
polar asters were detected, (Figure S3A), and g-tubulin
recruitment was not efficiently blocked (Figures S3A and
S3B). The cellular effects caused by ON01910 resem-
bled the phenotype that is caused by treatment with
low doses of microtubule depolymerizing agents rather
than Plk1 RNAi. Supporting this notion, depolymeriza-
tion of microtubules was clearly visible in interphase
cells when these were treated with higher doses of
ON01910 (Figure S3C). Thus, our data suggest that
Plk1 is not inhibited efficiently by ON01910 in human
cells, and this is in agreement with the undetectable in-
hibition of Plk1 in vitro. Taking into account the unknown
specificity of other recently published compounds[14, 15], our results suggest that BI 2536 is the first
potent and selective Plk1 inhibitor that induces all hall-
marks of Plk1 inhibition.
We next examined the ability of BI 2536, given by in-
travenous (i.v.) injection, to block the growth of human
cancer xenografts in immunodeficient, nu/numice. Con-
secutive cycles of 40–50 mg/kg BI 2536 given i.v. once or
twice per week were found to be highly efficacious in di-
verse xenograft models, such as the HCT 116 colon can-
cer with complete tumor suppression with the twice per
week schedule (treated versus the control (T/C) value
0.3%) and a T/C value of 16% with once per week treat-
ment (Figure 3A); both schedules were well-tolerated, as
judged by clinical signs and absence of major body-
weight changes (Figure S4). By using a more rigorous
model of larger HCT 116 tumors, in which treatment
was delayed until cancer nodules reached a median
size of 500 mm3, we found that five cycles of BI 2536
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319induced marked tumor regressions, whereas the control
mice showed progressive disease (Figure 3B). The effi-
cacy of BI 2536 was further studied in a pancreas-carci-
noma model, BxPC-3, and a non-small-cell lung-cancer
model, A549. By using the twice-weekly i.v. schedule
with four to seven cycles, we observed excellent tu-
mor-growth inhibition with T/C values of 5% and 14%,
respectively, in these two models (Figures 3C and 3D),
again with good tolerability.
The high selectivity of BI 2536 and the pattern of mi-
totic changes in BI 2536-treated cancer-cell cultures
suggest that the observed in vivo anticancer activity is
mediated by Plk1 inhibition. In line with this notion, we
have extended the biomarker studies of BI 2536 to the
in vivo setting. By employing immunohistochemical
methods, we found that BI 2536 inhibits the growth of
NCI-H460 lung carcinomas in nu/nu mice with a con-
comitant increase in mitotic index and upregulation of
histone H3 phosphorylation (Figure 3E, top panels). As
measured by TUNEL staining on tissue sections, mas-
sive tumor-cell apoptosis occurred approximately 48
hr after initiation of BI 2536 therapy (Figure 3E, bottom
panels).
With a view toward potential future clinical investiga-
tions in cancer patients, the biomarker studies were cor-
roborated by imaging methods suitable for noninvasive
and repeated in vivo monitoring, namely optical near-
infrared imaging and magnetic resonance imaging
(MRI). For optical imaging, we used the fluorescent dye,
Cy5.5, coupled to annexin V as a noninvasive in vivo
probe for apoptosis [16, 17] and monitored BI 2536 ef-
fects in the NCI-H460 lung-cancer model. As shown in
Figure 4A, we could readily visualize the surge in apo-
ptosis in the animal soon after initiation of treatment.
As a second approach, we employed noninvasive,
diffusion-weighted MRI scans to monitor changes in
the apparent diffusion coefficient of water (ADCw) as
a sensitive and reliable indicator of changes in the tumor
microenvironment [18, 19]. For these experiments, the
HCT 116 colon-cancer model was used with the fully ef-
fective twice weekly i.v. regimen of BI 2536 (Figure 4B).
Images and calculated ADCw values identified structural
changes in the tumors due to progressive apoptosis
starting on day 4 of the experiment, in agreement with
the results from immunohistochemistry and optical
imaging.
Collectively, our in vivo results indicate that BI 2536
not only inhibits cell proliferation by a mitotic arrest
but also subsequently induces tumor-cell death, consis-
tent with the observation that this compound can induce
tumor regressions.
Because all defective signaling pathways in a cancer
cell ultimately affect cell-cycle progression, a possible
approach for cancer therapy is to develop inhibitors
that block the function of a key element that is required
by cells to complete cell division. Functionally, Plk1 falls
into this group of targets including Aurora kinases [20,
21], which are specifically activated during mitosis and
highly expressed in human cancer tissues. In contrast
to Aurora kinases, little progress has been reported to-
ward potent and selective Plk1 inhibitors with drug-like
properties suited to clinical development. This initial re-
port on BI 2536, a Plk1 inhibitor from a novel chemical
series with attractive drug-like features, supports fourconclusions. First, it is chemically possible to generate
a Plk1 inhibitor with potency, selectivity, and pharmaco-
kinetic and physicochemical properties suitable for clin-
ical investigation in cancer patients: Initial results of BI
2536 administration in patients with locally advanced
or metastatic cancers have been reported [22]. Second,
mechanistic studies with human cancer cells in vitro
show that all of the cellular phenotypes that we have ob-
served can be fully explained by the ability of BI 2536 to
inhibit Plk1. Third, BI 2536 is highly effective in cancer
xenograft models in mice with acceptable tolerability.
Finally, we have profiled a number of preclinical, phar-
macodynamic markers, including noninvasive imaging
technologies, which may help to identify future clinical
biomarkers for Plk1 inhibitors. The results provide a clear
rationale that inhibition of Plk1 constitutes a new thera-
peutic approach and holds the potential to induce re-
gressions of a diverse range of cancer types.
Even if BI 2536 appears to be an extremely potent and
selective inhibitor of Plk1, we have observed inhibition
of Plk2 and Plk3 in vitro kinase activity at slightly higher
concentrations of BI 2536. Plk2 and Plk3 are not specif-
ically expressed in proliferating cells, are thought to
function in G1 and S phases of the cell cycle, and do
not appear to play a direct role in mitotic regulation
[1, 2, 4]. To address the specificity of BI 2536 treatment
in human cells, we compared its effects to published
Plk1 RNAi and Plk1 antibody injection experiments
[6, 7, 23, 24]. We found very positive correlations for all
phenotypes tested. BI 2536 mirrored effects of Plk1
RNAi in blocking the recruitment of g-tubulin and phos-
phorylation of Apc6 at mitotic centrosomes, inhibition of
cohesin release from chromosome arms, induction of
monopolar spindles, as well as a range of other mitotic
processes that are known to depend on Plk1 (see [25];
this issue of Current Biology). The facts that hallmarks
of Plk1 inhibition appeared and stabilized in a narrow
concentration range (10–100 nM) and no additional ef-
fects were observed up to 1 mM further support the
specificity of this inhibitor.
Plk1 inhibitors such as BI 2536 may have significant
advantages over existing antimitotic approaches (such
as taxanes and vinca alkaloids) that are directed at mi-
crotubules. The use of these latter agents can be con-
strained by dose-limiting toxicities related to the broad
requirement for tubulin in critical cellular processes un-
related to mitosis. Unlike tubulin, Plk1 is only expressed
in proliferating cells and appears to have no major role in
cellular processes outside of mitosis. Based on Plk1’s
essential and exquisite role during mitosis of all prolifer-
ating cells, an inhibitor would target all rapidly dividing
cells, irrespective of their sets of tumor suppressor or
oncogene mutations, yet avoid some of the side effects
associated with current antimitotic agents.
Supplemental Data
Supplemental Data include Experimental Procedures, four figures,
and one table and can be found with this article online at http://
www.current-biology.com/cgi/content/full/17/4/316/DC1/.
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320Figure 3. BI 2536 Shows Potent Efficacy and Good Tolerability In Vivo When Tested in Diverse Human Cancer Xenograft Models
(A) Nude mice bearing established HCT 116 tumors were treated i.v. for four cycles with either the vehicle control (indicated by blue squares) or BI
2536 at a dose of 40 mg/kg once weekly (indicated by green triangles) or twice weekly on two consecutive days (indicated by red triangles), n = 10
per group. Mean tumor volumes are shown. The symbols at the top of the graph indicate the treatment days. Mean tumor volume 6 SEM are
shown.
(B) HCT 116 tumor-bearing mice (average tumor starting volume:w500 mm3) were treated for five cycles with the vehicle control (indicated by
blue squares) or 50 mg/kg BI 2536 twice weekly on two consecutive days (indicated by red triangles). The tumor volume for each individual animal
was plotted over time. The triangles at the top of the graph indicate the treatment days.
(C) Nude mice bearing established BxPC-3 tumors were treated i.v. for four cycles with either the vehicle control (indicated by blue squares) or BI
2536 at a dose of 50 mg/kg twice weekly on two consecutive days (indicated by red triangles). n = 10 per treatment group. Mean tumor volumes
are shown. The triangles at the top of the graph indicate the treatment days. Data are mean 6 SEM.
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321Figure 4. Noninvasive Optical Imaging and MRI Scans Show the Induction of Apoptosis with BI 2536 Treatment In Vivo
(A) Nude mice carrying established NCI-H460 tumors subcutaneously in the chest wall were treated i.v. with the vehicle control or 60 mg/kg BI
2536. Mice were injected with Cy-annexin V 47 hr after the start of BI 2536 treatment, and images were taken for near-infrared fluorescence signal
1 hr later. Representative examples of false-color coded maps of the tumors are superimposed over corresponding near-infrared fluorescence
images of mice. Relative photon counts are indicated in the color scale bar. n = 4 animals per treatment group.
(B) Nude mice with established HCT 116 colon tumors were treated i.v. with the vehicle control or with 50 mg/kg BI 2536 on days 0 and 1. Mice
were examined by noninvasive MRI on days 0, 2, 4, and 7. Representative examples of axial slices from diffusion-weighted MRI (DWI) images and
superimposed false-color maps of the apparent diffusion coefficient of water (ADCw) in tumors for day 4 of the experiment of BI 2536- and ve-
hicle-treated (insert) mice are given. For assessment of the apoptotic cell shrinkage of the tumors, the mean ADCw values were determined for
each tumor at the various time points and are indicated in the chart. n = 6 animals per treatment group. A statistically significant increase (p =
0.044 versus vehicle-treated, p = 0.049 versus pretreatment) in ADCw was observed starting at day 4 of the experiment. Data are mean 6 SEM.and I. Waizenegger for insightful discussions. P. L. is supported by
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